Table 2.
Causes of drug failure at 24 month follow-up. Values are numbers (percentages) of participants
| Causes of drug failure | Unweighted cohort | Weighted cohort | |||||
|---|---|---|---|---|---|---|---|
| Rituximab (n=515) | Abatacept (n=347) | Tocilizumab (n=263) | Rituximab (n=480) | Abatacept (n=373) | Tocilizumab (n=315) | ||
| Death | 26 (5.0) | 19 (5.5) | 4 (1.5) | 25 (5.3) | 20 (5.3) | 14 (4.3) | |
| Introduction of a new biologic DMARD or combination of DMARDs | 206 (40.0) | 128 (36.9) | 171 (65.0) | 185 (38.6) | 164 (44.1) | 215 (68.3) | |
| Discontinuation of biologic | 454 (88.2) | 322 (92.8) | 241 (91.6) | 424 (88.5) | 347 (93.1) | 288 (91.3) | |
| Cause of discontinuation: | |||||||
| Death | 4 (0.9) | 0 (0.0) | 2 (0.9) | 3 (0.7) | 0 (0.0) | 4 (1.4) | |
| Adverse event | 64 (14.1) | 58 (18.0) | 97 (41.6) | 66 (15.7) | 58 (16.6) | 115 (42.5) | |
| Inefficacy | 332 (73.1) | 205 (63.7) | 107 (45.9) | 306 (72.1) | 224 (64.7) | 121 (44.5) | |
| Other reason | 54 (11.9) | 59 (18.3) | 27 (11.6) | 49 (11.5) | 65 (18.7) | 31 (11.6) | |
| Increase of corticosteroids dose (>10 mg/d of baseline) | 2 (0.4) | 6 (1.7) | 4 (1.5) | 2 (0.5) | 5 (1.5) | 3 (1.0) | |
DMARD=disease-modifying antirheumatic drug.
Unweighted cohort, raw data; weighted cohort, pseudo-population obtained after inverse probability weighting.